Year All2026202520242021 BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering August 6, 2026 BlossomHill Therapeutics Presents Initial Clinical Data from Dose Escalation in Ongoing Phase 1/1b Trial of Novel Macrocyclic CLK Inhibitor, BH-30236, in Patients with R/R AML or HR-MDS at EHA 2026 June 11, 2026 BlossomHill Therapeutics to Present Preliminary Results From Phase 1 Dose Escalation/Backfill Cohorts in Phase 1/2 SOLARA Trial of OMNI-EGFR Inhibitor, BH-30643, in Advanced EGFR-mutant NSCLC at the 2026 ASCO Annual Meeting May 21, 2026 BlossomHill Therapeutics Expands Board of Directors with the Appointments of Sheila Gujrathi, M.D., and John Schmid May 20, 2026 BlossomHill Therapeutics to Present Initial Clinical Dose Escalation Data from the Phase 1/1b Trial of BH-30236 in Patients with R/R AML or HR-MDS at EHA2026 May 12, 2026 BlossomHill Therapeutics Presents First Preclinical Data from New Pan-KRAS Inhibitor Program Built on a Novel Chemical Scaffold During Mini Symposium at AACR 2026 April 22, 2026 BlossomHill Therapeutics Unveils New Pan-KRAS Inhibitor Programs and Announces Upcoming Presentations at AACR Annual Meeting 2026 March 17, 2026 BlossomHill Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12 January 5, 2026
BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering August 6, 2026
BlossomHill Therapeutics Presents Initial Clinical Data from Dose Escalation in Ongoing Phase 1/1b Trial of Novel Macrocyclic CLK Inhibitor, BH-30236, in Patients with R/R AML or HR-MDS at EHA 2026 June 11, 2026
BlossomHill Therapeutics to Present Preliminary Results From Phase 1 Dose Escalation/Backfill Cohorts in Phase 1/2 SOLARA Trial of OMNI-EGFR Inhibitor, BH-30643, in Advanced EGFR-mutant NSCLC at the 2026 ASCO Annual Meeting May 21, 2026
BlossomHill Therapeutics Expands Board of Directors with the Appointments of Sheila Gujrathi, M.D., and John Schmid May 20, 2026
BlossomHill Therapeutics to Present Initial Clinical Dose Escalation Data from the Phase 1/1b Trial of BH-30236 in Patients with R/R AML or HR-MDS at EHA2026 May 12, 2026
BlossomHill Therapeutics Presents First Preclinical Data from New Pan-KRAS Inhibitor Program Built on a Novel Chemical Scaffold During Mini Symposium at AACR 2026 April 22, 2026
BlossomHill Therapeutics Unveils New Pan-KRAS Inhibitor Programs and Announces Upcoming Presentations at AACR Annual Meeting 2026 March 17, 2026
BlossomHill Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12 January 5, 2026